Elrexfio: Dosage Form, Projected Sales, NCE-1 Date | Elranatamab-Bcmm

Elrexfio

Elrexfio is a weekly subcutaneous injection for adults with relapsed or refractory multiple myeloma who have tried at least four prior treatments. It’s a bispecific antibody that directs T cells to attack myeloma cells by targeting BCMA and CD3.

The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.

Molecule Details :

Molecule Name :

Elranatamab-Bcmm
Innovator :

PFIZER
Approval Date :

14-Aug-23
Data Exclusivity Expiry :

14-Aug-27
Market Exclusivity Expiry :

14-Aug-35
Dosage Form :

Subcutaneous Injection
Strength :

44mg/1.1ml and 76mg/ 1.9ml
Therapeutic Category :

Anticancer
Revenue ($M) :

133

Year-wise Projected Sales ($M) :

2025 :

326
2026 :

469
2027 :

639
2028 :

814
2029 :

972
2030 :

1,107
2031 :

1,223

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Elrexfio

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?